#Taiwan #Taipei #Formosa Pharmaceuticals #Rxilient #APP13007

Formosa Pharmaceuticals' New Licensing Agreement

Formosa Pharmaceuticals, a leading biotechnology firm based in Taiwan, has recently made headlines with the announcement of an exclusive licensing agreement with Rxilient Medical Pte. Ltd. This partnership centers around the commercialization of clobetasol propionate ophthalmic suspension, branded as APP13007, which targets inflammation and pain following ocular surgeries.

Overview of the Agreement

This strategic collaboration is set to bring APP13007 to several key ASEAN markets, including Indonesia, the Philippines, Singapore, and Thailand. These regions are witnessing significant growth in ocular surgery, with estimates suggesting over 1 million procedures conducted annually. With both companies dedicated to excellence in patient care, this agreement serves as a stepping stone in expanding access to innovative ophthalmic treatments in emerging markets.

Key Components of the Licensing Agreement:

• - Upfront Payments: The agreement includes an initial payment upon signing.
• - Regulatory Milestones: Both companies will collaborate to navigate regulatory processes effectively.
• - Sales Milestones: Future payments will be based on sales performance, incentivizing both parties to promote APP13007 effectively.

The Product: APP13007

APP13007 is a patented formulation containing a superpotent corticosteroid, clobetasol propionate, developed through Formosa’s proprietary APNT® nanoparticle formulation technology. This technology enhances the drug's dissolution and bioavailability, addressing the challenges often faced by potent active pharmaceutical ingredients (APIs).

Approved by the U.S. FDA in 2024, the innovative formulation of APP13007 allows for a convenient dosing regimen of twice a day for 14 days, providing rapid relief from inflammation and pain with minimal adverse events. In a recent survey of 100 ophthalmic surgeons conducted in the United States, it was noted that approximately 80% of patients experienced a significant resolution of pain within four days post-surgery, further validating the efficacy of this treatment.

Vision for the Future

Erick Co, President and CEO of Formosa Pharmaceuticals, expressed enthusiasm for the partnership, stating, "We are pleased to establish this partnership with Rxilient, a prominent and growing regional corporation with global experience. We are confident that Rxilient's foundation, network, and commitment to innovative medicines will bring APP13007 to patients recovering from ocular surgery."

Similarly, Lawrence He, CEO of Rxilient, highlighted their focus on providing quality therapies to meet regional patient needs, affirming, "We are pleased to partner with Formosa and bring APP13007 to our markets, offering solutions for patients recovering from ocular surgery."

About the Companies

Formosa Pharmaceuticals, Inc. (6838.TW) is at the forefront of the clinical stage biotechnology industry, primarily focusing on ophthalmology and oncology. Their APNT® nanoparticle technology enables the development of viable formulations of drugs that are otherwise difficult to administer.

Rxilient, a fast-growing pharmaceutical company, operates extensively throughout Southeast Asia and the Middle East and North Africa. Their goal is to connect innovative healthcare solutions with patients in need, effectively transforming lives through accessible medical advancements.

With this newlicensing agreement, both Formosa and Rxilient are set to redefine post-surgical care for patients in the region, providing them with innovative solutions and enhancing their overall recovery experience. As they move forward, industry stakeholders and patients will be eager to see the positive impacts of this partnership on ocular health care in ASEAN markets.